eQ Oyj
25.3.2026 16:30:00 CET | Globenewswire | Press release
eQ Plc Managers' Transactions – Pertti Vanhanen
eQ Plc Managers' Transactions – Pertti Vanhanen
eQ Plc Managers' Transactions
25 March 2026 at 5:30 p.m.
eQ Plc announced on 2 March 2026, that Pertti Vanhanen has been appointed as the company’s Director of International Business and member of the Management Team. Vanhanen assumed his role on 2 March 2026 and has been granted options as a part of Option Program 2025 yesterday on 24 March 2026.
Person subject to the notification requirement
Name: Pertti Vanhanen
Position: Other senior manager
Issuer: eQ Oyj
LEI: 743700R4FA6AVH5J3D68
Notification type: INITIAL NOTIFICATION
Reference number: 149009/15/16
____________________________________________
Transaction date: 2026-03-24
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: eQ Oyj Optio-oikeudet 2025
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 70000 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 70000 Volume weighted average price: 0 EUR
eQ Plc
Additional information: Juha Surve, Group General Counsel, tel. +358 9 6817 8733
Distribution: Nasdaq Helsinki, www.eQ.fi
eQ is a Finnish group that concentrates on asset management and Corporate Finance business. eQ Asset Management offers a wide range of asset management services to both institutions and individuals. The assets managed by the Group total approximately EUR 13.8 billion. Advium Corporate Finance, which is part of the Group, offers services related to mergers and acquisitions, real estate transactions and equity capital markets. The parent company eQ Plc’s shares are listed on Nasdaq Helsinki. More information about the Group is available on our website www.eQ.fi.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
Genmab A/S23.10.2026 17:55:00 CEST | Press release
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom